Gradient Bioconvergence
- Company typePrivate
- Founded2017
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
Gradient Bioconvergence firmographics
Firmographics- Name
- Gradient Bioconvergence
- Legal name
- Gradiant Bioconvergence
- Website
- https://gradiantbio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Gradient Bioconvergence industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Gradient Bioconvergence is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Gradient Bioconvergence business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Efficacy Evaluation Services: Contract service providing drug efficacy evaluation using proprietary PDO platforms for pharmaceutical and biotech companies.
- Biomarker Discovery Services: AI-based biomarker discovery services for drug response prediction and patient stratification.
- Target Discovery Services: Novel anticancer target identification and validation services using PDO and AI platforms.
- Licensing Royalties: Technology licensing including decellularized scaffold patents and organoid culture technology to other biotech companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Gradient Bioconvergence product offering
Product offeringCore offering
Gradient Bioconvergence develops patient-derived organoids (PDOs) for cancer research and drug development. The company operates Asia's largest PDO banking system with approximately 1,000 organoid types paired with NGS genomic and clinical data, and combines this with proprietary AI algorithms to deliver drug efficacy evaluation, AI-driven anticancer target discovery, biomarker identification, and iPSC-derived organoid research services to pharmaceutical and biotech clients. It also advances its own drug candidate GBC-11004, a third-generation kinase inhibitor for EGFR-resistant NSCLC.
Product overview
Gradient Bioconvergence operates a platform-plus-services model centered on patient-derived organoid (PDO) technology for drug discovery. The core offerings include PDO Banking (Asia's largest organoid bank with ~1,000 species paired with genomic and clinical data), the AI-Driven Target Discovery platform (combining PDO data with proprietary AI algorithms for target identification), iPSC-Derived Organoid Research services for brain disease modeling, Biomaterials for optimized organoid culture, an Immunotherapy Screening Platform using co-culture systems, and the proprietary drug candidate GBC-11004 (a kinase inhibitor for resistant NSCLC). The company licenses HUB organoid technology and employs CRISPR-based validation alongside its AI capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- PDO Banking Asia's largest Patient-Derived Organoid banking service with approximately 1,000 organoid species, each paired with patient clinical information and genomic data (NGS), used by pharmaceutical and biotech clients for drug efficacy evaluation and novel target discovery.
- AI-Driven Target Discovery AI-driven anticancer target discovery service that combines PDO big data with proprietary AI algorithms to identify high-confidence targets, validated through PDO-based CRISPR systems, for pharmaceutical and biotech partners.
- iPSC-Derived Organoid Research Customized research services using human induced pluripotent stem cell (hiPSC)-derived brain organoids for degenerative brain disease research, including co-culture models with microglia, for pharmaceutical and academic clients.
- Biomaterials Decellularized scaffold and culture materials optimized for organoid culture, enabling 3D culture and tissue environment simulation for organoid development, supplied to research and biotech customers.
- Immunotherapy Screening Platform Co-culture service combining patient-derived organoids with autologous immune cells for immunotherapy efficacy verification, enabling personalized cancer treatment screening for pharmaceutical and biotech clients.
- GBC-11004 A proprietary novel 3rd generation kinase inhibitor drug candidate targeting EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), being developed by Gradient Bioconvergence for global licensing partnerships.
Quantifiable outcome
- Drug development timeline reduction from over 10 years to 1-2 years with AI-based target discovery and PDO validation
- +3 more outcomes
Companies that use Gradient Bioconvergence
Customer profileSegments3 records
Ideal customer profiles3 records
Gradient Bioconvergence technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Gradient Bioconvergence partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core, major and minor.
- Chonnam National University Hwasun HospitalcoreMOU with Chonnam National University Hwasun Hospital for anticancer drug response prediction and cancer organoid bank construction. The collaboration integrates patient-based clinical information with organoid analysis data to improve anticancer drug response prediction accuracy.
- OmicInsightcoreStrategic partnership with US Silicon Valley biotech company OmicInsight to integrate patient-derived organoid (PDO) platforms with spatial omics analysis technology for precision medicine research. The collaboration aims to enable deeper insight into tissue architecture, disease progression, and therapeutic response for drug discovery, precision medicine, and regenerative medicine.
- Dong-A STcoreJoint research agreement with Korean pharmaceutical company Dong-A ST for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders. Leverages organoid analysis, genomic big data, and automated drug discovery platforms to reduce development timelines from over 10 years to 1-2 years and cut costs by 15-30 percent.
- Yonsei Medical CentercoreJoint research contract for PDO co-culture and immunotherapy screening platform development with Yonsei Medical Center. Expanding collaboration from lung cancer to pancreatic cancer and ovarian cancer organoid research.
- BCChemmajorMOU with BCChem for first-in-class anticancer drug development. Collaboration to discover novel lung cancer targets using AI-based PDO platform and develop targeted anticancer drugs using BCChem's low-molecular weight synthesis technology.
- Syntec BiomajorMOU with AI drug development company Syntec Bio for building an organoid-based AI drug development platform and developing novel targeted anticancer drugs. Combines PDO-based drug response evaluation with Syntec's AI candidate substance discovery platform.
- Strand TherapeuticsmajorResearch cooperation agreement with US mRNA therapy developer Strand Therapeutics for next-generation mRNA therapy development. Using organoid and immune cell co-culture platform to verify mRNA therapy efficacy for solid tumor treatment.
- Dr. Noah BiotechmajorJoint research agreement with AI drug development company Dr. Noah Biotech for rare disease treatment development. Combining PDO platform with AI-based drug development platform (ARK platform) for rare disease drug discovery.
- HLB BiostepmajorJoint business MOU with preclinical CRO HLB Biostep for patient-derived organoid xenograft (PDOX) model development. Building on-demand PDOX production line using company's PDO banking and HLB Biostep's in vivo testing capabilities.
- CurevusminorBrain organoid related cooperation agreement with KIST research institute company Curevus for neurodegenerative disease research.
- Medilife ScienceminorCooperation for non-small cell lung cancer biomarker discovery using company's PDO platform.
- Kangwon National UniversityminorEquipment donation and MOU for anticancer drug development research. Company donated anaerobic chamber for organoid and microbiome research, and will perform efficacy evaluation of Kangwon National University's anticancer drug candidates.
- Korea University Anam HospitalcoreMOU with Korea University Anam Hospital and Oncomaster for patient-derived organoid establishment and precision medicine commercialization. Building PDO system for bladder and lung cancer patients for personalized medical services.
- OncomasterminorPrecision medicine AI company collaborating with company and Korea University Anam Hospital for developing clinical decision support system (CDSS) based on clinical and genomic information for personalized treatment recommendations.
- HUB (Hubrecht Organoid Technology)coreLicensing agreement for organoid technology and technology transfer from Netherlands-based HUB, first such agreement in Korea. Provides access to world-recognized organoid culture methodology pioneered by Dr. Sato Toshiro.
- Dr. Sato ToshirocoreWorld pioneer in organoid technology, first to successfully culture intestinal organoids in 2009, recruited as scientific advisory board member to enhance organoid culture technology and strengthen intellectual property.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Gradient Bioconvergence competitors and assessment
Company assessmentDirect peers
- Crown Bioscience: Crown Bioscience operates one of the largest commercial PDX and patient-derived model biobanks for oncology drug discovery and efficacy evaluation, directly competing with Gradient's PDO banking and efficacy-evaluation services for global pharma.
- XtalPi: XtalPi combines AI-driven computational chemistry with automated drug discovery platforms and is a named Gradient collaboration partner; both target AI-enabled small-molecule and biologic discovery for global pharma.
Broad incumbents
- Charles River Laboratories: Charles River is a global CRO offering preclinical oncology, organoid, and biomarker services; it competes for the same pharma R&D budgets as Gradient's efficacy-evaluation and biomarker-discovery offerings, though as part of a much broader services portfolio.
- Tempus AI: Tempus builds a large multimodal clinical and genomic data library used for AI-driven precision medicine and biomarker discovery; comparable in the data + AI layer behind Gradient's biomarker and target discovery work.
Emerging players
- Recursion Pharmaceuticals: Recursion uses AI and high-throughput biology for drug discovery; comparable as a tech-first platform pursuing AI-driven target ID, though it relies more on cell-based imaging than organoid biology.
- Insitro: Insitro applies ML to biology for drug discovery, including iPSC-derived disease models; comparable in the AI + human-relevant model intersection, though it focuses more on iPSC and genomics than PDO oncology banking.
- Synlogic: Synlogic develops engineered microbial and synthetic biology therapeutics with a platform model; partial overlap in the organoid/biology-platform narrative, but more focused on therapeutic development than preclinical services.
- CytoReason: CytoReason applies AI to proprietary human disease models and omics data for pharma drug discovery; comparable as an AI-driven model-based discovery platform serving global pharma, though focused on computational immune/inflammation models.
Others
- Personalis: Personalis provides genomic sequencing and analytics for clinical and translational research; comparable as a genomics data partner/adjacent in precision oncology workflows involving PDO response and genomic integration.
- Hubrecht Organoid Technology (HUB): HUB is the licensor of Gradient's core organoid culture IP and the foundational player in the organoid technology space; an enabling/ecosystem peer rather than a direct competitor in services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Gradient Bioconvergence social profiles
Digital presenceGradient Bioconvergence financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gradient Bioconvergence leadership team
Management profileNumber of profiles
Profiles1 record
Gradient Bioconvergence funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gradient Bioconvergence M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gradient Bioconvergence
What does Gradient Bioconvergence do?
Gradient Bioconvergence develops patient-derived organoids (PDOs) for cancer research and drug development. The company operates Asia's largest PDO banking system with approximately 1,000 organoid types paired with NGS genomic and clinical data, and combines this with proprietary AI algorithms to deliver drug efficacy evaluation, AI-driven anticancer target discovery, biomarker identification, and iPSC-derived organoid research services to pharmaceutical and biotech clients. It also advances its own drug candidate GBC-11004, a third-generation kinase inhibitor for EGFR-resistant NSCLC.
Is Gradient Bioconvergence a public or private company?
Gradient Bioconvergence is a private company. It is classified as corporate owned and is currently operating.
When was Gradient Bioconvergence founded?
Gradient Bioconvergence was founded in 2017. It employs 11 to 50 people.
Where is Gradient Bioconvergence based?
Gradient Bioconvergence is headquartered in Seoul, South Korea, in the Asia region.
How does Gradient Bioconvergence make money?
Four revenue lines are on record. Drug Efficacy Evaluation Services are the primary driver. The others are biomarker Discovery Services, target Discovery Services and licensing Royalties.
Who are Gradient Bioconvergence's main competitors?
Direct peers on record are Crown Bioscience and XtalPi. Broad incumbents are Charles River Laboratories and Tempus AI. Emerging players are Recursion Pharmaceuticals, Insitro, Synlogic and CytoReason. Others are Personalis and Hubrecht Organoid Technology (HUB).
Does Gradient Bioconvergence have an API?
No public API is recorded for Gradient Bioconvergence.
What industry is Gradient Bioconvergence in?
Gradient Bioconvergence's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.